{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:41Z","timestamp":1792782521909,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad de Navarra","id":[{"id":"https:\/\/ror.org\/02rxc7m23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the sources of variability in Centiloid (CL) calculations, particularly the influence of image reconstruction and reference region selection, and to examine the relationship between baseline CL scores, visual interpretation and subsequent disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>162 aMCI patients who underwent amyloid PET at a single center were retrospectively analyzed. Visual assessment was performed by two nuclear medicine physicians and Centiloid scoring was determined using syngo.MI Neurology Cortical Analysis, using different reference regions (RR) and image reconstruction settings. The CL values were compared against visual interpretation, using a ROC analysis. The value of CL in predicting the onset of Alzheimer's dementia was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The use of the whole cerebellum as RR provided the most robust and consistent CL values across reconstruction methods. The RR was critical in the case of flutemetamol, as CL varied in more than 20 units between pons and whole cerebellum. Visual classifications and CL values showed strong concordance (area under the ROC curve: 0.9786) and the CL cut-off value that maximized agreement with visual reading was 28 CL. During follow-up, 49% of patients progressed to AD dementia and CL-based amyloid positivity was a significant predictor of progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Standardized CL quantification using the whole cerebellum as RR enhances the reliability of amyloid PET interpretation across tracers and reconstruction settings. CL values strongly correlate with visual assessment and are predictive of clinical progression. These findings suggest the potential utility of CL quantification in both clinical and research settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07943-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:39:20Z","timestamp":1785569960000},"page":"7538-7547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment"],"prefix":"10.1007","volume":"53","author":[{"given":"Katharina C. E.","family":"Hirschm\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-1210","authenticated-orcid":false,"given":"Elena","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar F.","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Echeveste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Romera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Riverol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"7943_CR1","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63:13S-19S. https:\/\/doi.org\/10.2967\/jnumed.121.263195.","journal-title":"J Nucl Med"},{"key":"7943_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"key":"7943_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","volume":"9","author":"S Salloway","year":"2017","unstructured":"Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Performance of [ 18 F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA\u2010AA recommendations for the neuropathologic diagnosis of Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2017;9:25\u201334. https:\/\/doi.org\/10.1016\/j.dadm.2017.06.001.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"7943_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement"},{"key":"7943_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM. Use of Florbetapir-PET for imaging \u03b2-amyloid pathology. JAMA. 2011;305:275. https:\/\/doi.org\/10.1001\/jama.2010.2008.","journal-title":"JAMA"},{"key":"7943_CR6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","volume":"57","author":"S Minoshima","year":"2016","unstructured":"Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57:1316\u201322. https:\/\/doi.org\/10.2967\/jnumed.116.174615.","journal-title":"J Nucl Med"},{"key":"7943_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2967\/jnumed.122.264031","volume":"64","author":"AM Smith","year":"2023","unstructured":"Smith AM, Obuchowski NA, Foster NL, Klein G, Mozley PD, Lammertsma AA, et al. The RSNA QIBA profile for amyloid PET as an imaging biomarker for cerebral amyloid quantification. J Nucl Med. 2023;64:294\u2013303. https:\/\/doi.org\/10.2967\/jnumed.122.264031.","journal-title":"J Nucl Med"},{"key":"7943_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118775","volume":"246","author":"L Iaccarino","year":"2022","unstructured":"Iaccarino L, La Joie R, Koeppe R, Siegel BA, Hillner BE, Gatsonis C, et al. rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neuroimage. 2022;246:118775. https:\/\/doi.org\/10.1016\/j.neuroimage.2021.118775.","journal-title":"Neuroimage"},{"key":"7943_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800. https:\/\/doi.org\/10.1212\/WNL.58.12.1791.","journal-title":"Neurology"},{"key":"7943_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol"},{"issue":"1","key":"7943_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"key":"7943_CR12","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition [Internet]. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},{"key":"7943_CR13","unstructured":"Jovaleki\u0107 A, Ro\u00e9-Vellv\u00e9 N, Koglin N, Lagos Quintana M, Nelson A, Diemling M, et al. Analysis of 15 software pipelines for validation of [ 18 F]florbetaben PET quantitation. Hermes Medical Solutions. 2022."},{"key":"7943_CR14","doi-asserted-by":"crossref","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging and Alzheimer\u2019s Association workgroup. Alzheimer\u2019s and Dementia: Elsevier; 2011.","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"7943_CR15","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1007\/s00259-025-07275-2","volume":"52","author":"B Echeveste","year":"2025","unstructured":"Echeveste B, Prieto E, Guill\u00e9n EF, Jimenez A, Montoya G, Villino R, et al. Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer\u00b4s disease in the clinical practice. Eur J Nucl Med Mol Imaging. 2025;52:3567\u201377. https:\/\/doi.org\/10.1007\/s00259-025-07275-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7943_CR16","volume-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging and the Alzheimer\u2019s Association workgroup","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging and the Alzheimer\u2019s Association workgroup. Alzheimer\u2019s and Dementia: Elsevier; 2011."},{"issue":"3","key":"7943_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of Flutemetamol labeled with radioactive Fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4144.","journal-title":"JAMA Neurol"},{"key":"7943_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(11)70077-1.","journal-title":"Lancet Neurol"},{"key":"7943_CR19","unstructured":"Fahmi R. 2025 White Paper. syngo.MI Neurology Cortical Analysis. Standardization of amyloid PET quantification using the Centiloid scale"},{"key":"7943_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135. https:\/\/doi.org\/10.1002\/1097-0142(1950)3:1%3c32::AID-CNCR2820030106%3e3.0.CO;2-3.","journal-title":"Cancer"},{"key":"7943_CR21","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Ro\u00e9\u2010Vellv\u00e9 N, et al. Centiloid recommendations for clinical context\u2010of\u2010use from the AMYPAD consortium. Alzheimers Dement. 2024;20:9037\u201348. https:\/\/doi.org\/10.1002\/alz.14336.","journal-title":"Alzheimers Dement"},{"key":"7943_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/alz.055726","author":"M Shekari","year":"2021","unstructured":"Shekari M, Salvad\u00f3 G, Battle MR, Collij LE, Heeman F, Alves IL, et al. Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. Alzheimers Dement. 2021. https:\/\/doi.org\/10.1002\/alz.055726.","journal-title":"Alzheimers Dement"},{"key":"7943_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:1\u20138. https:\/\/doi.org\/10.1186\/s13195-020-00587-5.","journal-title":"Alzheimers Res Ther"},{"key":"7943_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/alz.12696","volume":"19","author":"D Altomare","year":"2023","unstructured":"Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, et al. Description of a European memory clinic cohort undergoing amyloid\u2010PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimers Dement. 2023;19:844\u201356. https:\/\/doi.org\/10.1002\/alz.12696.","journal-title":"Alzheimers Dement"},{"key":"7943_CR25","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, V\u00e1llez Garc\u00eda D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20:5102\u201313. https:\/\/doi.org\/10.1002\/alz.13883.","journal-title":"Alzheimers Dement"},{"key":"7943_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnumed.125.270607","volume":"00","author":"J Zhang","year":"2025","unstructured":"Zhang J, Soleimani-Meigooni DN, Koeppe R, Ackley S, Schonhaut DR, Lin ZE, et al. Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy. J Nucl Med. 2025;00:1\u20139. https:\/\/doi.org\/10.2967\/jnumed.125.270607.","journal-title":"J Nucl Med"},{"key":"7943_CR27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1177\/13872877241313063","volume":"103","author":"A Gillman","year":"2025","unstructured":"Gillman A, Bourgeat P, Cox T, Villemagne VL, Fripp J, Huang K, et al. Digital detector PET\/CT increases Centiloid measures of amyloid in Alzheimer\u2019s disease: a head-to-head comparison of cameras. J Alzheimers Dis. 2025;103:1257\u201368. https:\/\/doi.org\/10.1177\/13872877241313063.","journal-title":"J Alzheimers Dis"},{"key":"7943_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2022.119527","volume":"262","author":"P Bourgeat","year":"2022","unstructured":"Bourgeat P, Dor\u00e9 V, Burnham SC, Benzinger T, Tosun D, Li S, et al. \u03b2-amyloid PET harmonisation across longitudinal studies: application to AIBL, ADNI and OASIS3. Neuroimage. 2022;262:119527. https:\/\/doi.org\/10.1016\/j.neuroimage.2022.119527.","journal-title":"Neuroimage"},{"key":"7943_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2967\/jnumed.123.266188","volume":"65","author":"GP Ruwanpathirana","year":"2024","unstructured":"Ruwanpathirana GP, Williams RC, Masters CL, Rowe CC, Johnston LA, Davey CE. Impact of PET reconstruction on Amyloid-\u03b2 quantitation in cross-sectional and longitudinal analyses. J Nucl Med. 2024;65:781\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266188.","journal-title":"J Nucl Med"},{"key":"7943_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.045294","volume":"16","author":"M Shekari","year":"2020","unstructured":"Shekari M, Ni\u00f1erola-Baiz\u00e1n A, Salvad\u00f3 G, Battle MR, Buckley C, Farrar G, et al. Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. Alzheimers Dement. 2020;16:e045294. https:\/\/doi.org\/10.1002\/alz.045294.","journal-title":"Alzheimers Dement"},{"key":"7943_CR31","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.2967\/jnumed.124.268754","volume":"66","author":"J Arbizu","year":"2025","unstructured":"Arbizu J, Morbelli S, Minoshima S, Barthel H, Kuo P, Van Weehaeghe D, et al. SNMMI procedure standard\/EANM practice guideline for brain [18F]FDG PET imaging, Version 2.0. J Nucl Med. 2025;66:S45-60. https:\/\/doi.org\/10.2967\/jnumed.124.268754.","journal-title":"J Nucl Med"},{"key":"7943_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ejmp.2015.07.001","volume":"31","author":"E Prieto","year":"2015","unstructured":"Prieto E, Mart\u00ed-Climent JM, Mor\u00e1n V, Sancho L, Barb\u00e9s B, Arbizu J, et al. Brain PET imaging optimization with time of flight and point spread function modelling. Phys Med. 2015;31:948\u201355. https:\/\/doi.org\/10.1016\/j.ejmp.2015.07.001.","journal-title":"Phys Med"},{"key":"7943_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.748198","volume":"13","author":"SJ Teipel","year":"2021","unstructured":"Teipel SJ, Dyrba M, Vergallo A, Lista S, Habert MO, Potier M-C, et al. Partial volume correction increases the sensitivity of 18F-Florbetapir-Positron Emission Tomography for the detection of early stage amyloidosis. Front Aging Neurosci. 2021;13:748198. https:\/\/doi.org\/10.3389\/fnagi.2021.748198.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"7943_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40658-023-00588-X","volume":"10","author":"M Shekari","year":"2023","unstructured":"Shekari M, Verwer EE, Yaqub M, Daamen M, Buckley C, Frisoni GB, et al. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan. EJNMMI Phys. 2023;10(1):1. https:\/\/doi.org\/10.1186\/S40658-023-00588-X.","journal-title":"EJNMMI Phys"},{"key":"7943_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107. https:\/\/doi.org\/10.1186\/s13550-018-0456-7.","journal-title":"EJNMMI Res"},{"key":"7943_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/tomography11080086","volume":"11","author":"Y Kang","year":"2025","unstructured":"Kang Y, Min JW, Kwon SJ, Ha S. Reliability of automated amyloid PET quantification: real-world validation of commercial tools against Centiloid project method. Tomography. 2025;11:86. https:\/\/doi.org\/10.3390\/tomography11080086.","journal-title":"Tomography"},{"key":"7943_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","volume":"38","author":"C Shang","year":"2024","unstructured":"Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, et al. Comparison of consistency in Centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. Ann Nucl Med. 2024;38:460\u20137. https:\/\/doi.org\/10.1007\/s12149-024-01919-3.","journal-title":"Ann Nucl Med"},{"key":"7943_CR38","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","volume":"50","author":"A Jovalekic","year":"2023","unstructured":"Jovalekic A, Ro\u00e9-Vellv\u00e9 N, Koglin N, Quintana ML, Nelson A, Diemling M, et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging. 2023;50:3276\u201389. https:\/\/doi.org\/10.1007\/s00259-023-06279-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7943_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70163","author":"FP DiFilippo","year":"2025","unstructured":"DiFilippo FP, Rao SM. Evaluation of two clinical Centiloid analysis products for 18 F\u2010florbetapir PET in cognitively unimpaired elders. Alzheimers Dement Diagn Assess Dis Monit. 2025. https:\/\/doi.org\/10.1002\/dad2.70163.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"7943_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in Centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13:99. https:\/\/doi.org\/10.1186\/s13195-021-00836-1.","journal-title":"Alzheimers Res Ther"},{"key":"7943_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302\u201310. https:\/\/doi.org\/10.1007\/s00259-020-04942-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7943_CR42","doi-asserted-by":"publisher","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22. https:\/\/doi.org\/10.1186\/s13195-020-00587-.","DOI":"10.1186\/s13195-020-00587-"},{"key":"7943_CR43","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14:1565\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353.","journal-title":"Alzheimers Dement"},{"key":"7943_CR44","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","volume":"82","author":"E Zeltzer","year":"2025","unstructured":"Zeltzer E, Schonhaut DR, Mundada NS, Blazhenets G, Soleimani-Meigooni DN, Cho H, et al. Concordance between Amyloid-PET quantification and real-world visual reads. JAMA Neurol. 2025;82:952\u2013952. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2218.","journal-title":"JAMA Neurol"},{"key":"7943_CR45","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1007\/s00259-025-07270-7","volume":"52","author":"GD Kolinger","year":"2025","unstructured":"Kolinger GD, Sotolongo-Grau O, Ro\u00e9-Vellv\u00e9 N, Tartari JP, Sanabria \u00c1, P\u00e9rez-Mart\u00ednez E, et al. Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study. Eur J Nucl Med Mol Imaging. 2025;52:3578\u201390. https:\/\/doi.org\/10.1007\/s00259-025-07270-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7943_CR46","doi-asserted-by":"publisher","first-page":"E650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer Disease with the pattern of Tau- and Amyloid-PET. Neurology. 2021;96:E650-61. https:\/\/doi.org\/10.1212\/WNL.0000000000011270.","journal-title":"Neurology"},{"key":"7943_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurobiolaging.2020.06.001","volume":"95","author":"SC Burnham","year":"2020","unstructured":"Burnham SC, Laws SM, Budgeon CA, Dor\u00e9 V, Porter T, Bourgeat P, et al. Impact of APOE-\u03b54 carriage on the onset and rates of neocortical A\u03b2-amyloid deposition. Neurobiol Aging. 2020;95:46\u201355. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.06.001.","journal-title":"Neurobiol Aging"},{"key":"7943_CR48","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1002\/alz.13761","volume":"20","author":"A Bollack","year":"2024","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: results from the AMYPAD prognostic and natural history study. Alzheimers Dement. 2024;20:3429\u201341. https:\/\/doi.org\/10.1002\/alz.13761.","journal-title":"Alzheimers Dement"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07943-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:02Z","timestamp":1790929922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7943"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07943-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for the use of their data in research, and the study protocol was approved by the Ethics Research Committee of the Universidad de Navarra.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R. Fahmi is a full-time employee of Siemens Medical Solutions USA, Inc. J. Arbizu has received institutional grant support from Siemens Healthineers and Life Molecular Imaging, and speaker\/advisory honoraria from Siemens Healthineers, Life Molecular Imaging (Lantheus), Eli Lilly, Advanced Accelerator Applications (Novartis), Biogen, Zambon, and GE Healthcare.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}